Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
ANN ARBOR, Mich., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units ( RSUs ) under Esperion's 2017 Inducement Equity Incentive Plan.
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Esperion ( ESPR ) Q2 Revenue Jumps 12%
Esperion Therapeutics ( NASDAQ:ESPR ) , a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5, 2025, it reported results. Revenue ( GAAP ) was $82.4 million, well above the analyst estimate of ...
Esperion Therapeutics ( ESPR ) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
- Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million ...
Earnings Preview: Crinetics Pharmaceuticals, Inc. ( CRNX ) Q2 Earnings Expected to Decline
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences ( NBIX ) Q2 Earnings and Revenues Beat Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report Second Quarter 2025 Financial Results on August 5
ANN ARBOR, Mich., July 22, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board
BOSTON, July 15, 2025 ( GLOBE NEWSWIRE ) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of Scott Braunstein, M.D., as Chairman of the Board.
Esperion Appoints Craig Thompson to Board of Directors - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., July 01, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director.
Esperion Appoints Craig Thompson to Board of Directors
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience ...
Why Is Esperion Therapeutics ( ESPR ) Up 28.6% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® ( bempedoic acid ) Prior to April 19, 2040 - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., June 02, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited ( together, Hetero USA ) .
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® ( bempedoic acid ) Prior to April 19, 2040 - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., May 12, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited ( together, Micro Labs ) .
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® ( bempedoic acid ) Prior to April 19, 2040
ANN ARBOR, Mich., May 12, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited ( together, Micro Labs ) . This agreement resolves the patent litigation brought by ...
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
ANN ARBOR, Mich., May 09, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
ANN ARBOR, Mich., May 08, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units ( RSUs ) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® ( bempedoic acid ) and NEXLIZET® ( bempedoic acid and ezetimibe ) in Canada - Esperion Therapeutics ( NASDAQ:ESPR )
- Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales - - Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease -
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn ( OTC:CYDY )
VANCOUVER, Washington, May 06, 2025 ( GLOBE NEWSWIRE ) -- CytoDyn Inc. CYDY ( "CytoDyn" or the "Company" ) , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E.
Esperion Therapeutics ( ESPR ) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -16.67% and 12.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical ( COLL ) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Participate in The Citizens Life Sciences Conference - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., April 25, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion ...
Esperion to Participate in The Citizens Life Sciences Conference
ANN ARBOR, Mich., April 25, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Esperion Therapeutics ( ESPR ) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., April 10, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City.
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Highlighting Novel Insights into ATP Citrate Lyase ( ACLY ) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase ( ACLY ) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases ...
Esperion Therapeutics ( ESPR ) Down 15.8% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.
Esperion Therapeutics ( ESPR ) Reports Q4 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 28.57% and 1.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
- FY24 Total Revenue Grew 186% Y/Y to $332.3 Million. FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million ...
Xeris Biopharma ( XERS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Esperion Therapeutics ( ESPR ) Report Negative Earnings Next Week? What You Should Know
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
ANN ARBOR, Mich., Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units ( RSUs ) under Esperion's 2017 Inducement Equity Incentive Plan.
Ardelyx ( ARDX ) Moves 16.0% Higher: Will This Strength Last?
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Esperion Therapeutics ( NASDAQ:ESPR )
- Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease -
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
- $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt ...
Esperion Partners with Neopharm to Commercialize NEXLETOL® ( bempedoic acid ) and NEXLIZET® ( bempedoic acid and ezetimibe ) in Israel - Esperion Therapeutics ( NASDAQ:ESPR )
- Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales - - Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years -
Esperion Partners with Neopharm to Commercialize NEXLETOL® ( bempedoic acid ) and NEXLIZET® ( bempedoic acid and ezetimibe ) in Israel
- Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales ...
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® ( bempedoic acid ) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
- An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo ...
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
Esperion Therapeutics ( ESPR ) Reports Q3 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -7.14% and 6.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
- Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth ...
Aquestive Therapeutics ( AQST ) Reports Q3 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -8.33% and 6.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
